Table 1 Characteristics of all included patients
Characteristics of Patients | All (n = 379) | No AF (n = 173, 46%) | AF (n = 206, 54%) | No AF vs. AF |
|---|---|---|---|---|
Demographics at CRT implantation | ||||
Age (IQR) | 71 (62–76) | 69 (59–75) | 72 (66–76) | 0.026 |
Male | 85% | 81% | 88% | 0.04 |
Ischemic heart disease | 57% | 55% | 59% | 0.40 |
NYHA Class III or IV | 91% | 89% | 92% | 0.34 |
Hypertension | 36% | 36% | 35% | 0.8 |
Diabetes | 34% | 32% | 35% | 0.5 |
Conventional PM before CRT | 24% | 17% | 30% | 0,003 |
Creatinine (IQR) | 110 (90–137) | 110 (90–136) | 114 (89–139) | 0.57 |
Medication at CRT implantation | ||||
β-Blocker | 82% | 82% | 82% | 0.9 |
ACEi or ARB | 94% | 96% | 93% | 0.16 |
Loop diuretic | 92% | 92% | 93% | 0.7 |
Class I or III antiarrhythmic | 14% | 8% | 29% | 0.003 |
Digoxin | 37% | 30% | 42% | 0.01 |
Warfarin | 55% | 32% | 75% | < 0.001 |
Cardiac findings at CRT implantation | ||||
QRS Duration ms (IQR) | 170 (154–184) | 170 (154–184) | 170 (152–184) | 0.98 |
LV ejection fraction (IQR) | 22 (20–25) | 22 (20–25) | 22 (20–27) | 0.98 |
LBBB | 62% (236) | 72% (125) | 54% (53) | < 0.001 |
Follow-up characteristics | ||||
CRT-P implanted | 74% | 75% | 73% | 0.78 |
Median follow-up months (IQR) | 40 (11–83) | 59 (23–89) | 30 (5–76) | < 0.001 |
BivP first year of follow-up 98% or less | 35% | 22% | 48% | < 0.001 |
Death during follow-up | 232 (61%) | 88 (51%) | 144 (70%) | < 0.001 |
HTx during follow-up | 13 (3%) | 6 (3%) | 7 (3%) | 0.97 |